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ORIGINAL ARTICLEEffects of Parvovirus B19 In Vitro Infection on
Monocytes from Patients with Systemic
Sclerosis: Enhanced Inflammatory Pathways by
Caspase-1 Activation and Cytokine Production
Krystyna Zakrzewska1,4, Rosaria Arvia1,4, Maria Gabriella Torcia1,4, Ann Maria Clemente1,
Michele Tanturli2, Giuseppe Castronovo2, Gianluca Sighinolfi3, Dilia Giuggioli3 and Clodoveo Ferri3Parvovirus B19 (B19V) has been proposed as a triggering agent for some autoimmune diseases including sys-
temic sclerosis (SSc). In this study, we investigated whether B19V infection in vitro differently activates in-
flammatory pathways, including those dependent on caspase-1 activation, in monocytes from patients with SSc
and healthy controls. We showed that B19V can infect both THP-1 cells and primary monocytes but is not able
to replicate in these cells. B19V infection increases the production of tumor necrosis factor-a and induces
NLRP3-mediated caspase-1 activation in both THP-1 cells differentiated with phorbol 12-myristate 13-acetate
and in monocytes from patients with SSc but not from healthy controls. B19V infection was sufficient for
THP-1 to produce mature IL-1b. Monocytes from patients with SSc required an additional stimulus, here rep-
resented by lipopolysaccharides, to activate cytokine genes. Following B19V infection, however,
lipopolysaccharide-activated monocytes from patients with SSc strongly increased the production of IL-1b and
tumor necrosis factor-a. Altogether, these data suggest that viral components might potentiate the response to
endogenous and/or exogenous toll-like receptor 4 ligands in monocytes from patients with SSc. The B19V-
mediated activation of inflammatory pathways in monocytes might contribute to the disease progression
and/or development of specific clinical phenotypes.
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Systemic sclerosis (SSc) is a complex autoimmune disease
characterized by vascular and immunological abnormalities
with progressive fibrosis involving the skin and internal organs.
Themain hallmarks of this disease are injury to the endothelial
cells, overproduction of extracellular matrix proteins, and
aberrant activation of both immune and nonimmune effector
cells (Le Roy, 1992). Innate immune response plays a relevant
role in the pathogenesis of SSc (O’Reilly, 2014).
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with healthy subjects (Dantas et al., 2018; Duan et al., 2008).
In addition, recent evidence has placed the chronic activa-
tion of the inflammasome and the production of the
“inflammasome proteins” as central drivers of fibrosis (Artlett
et al., 2011). Although the nature of triggers inducing the
activation of innate immunity in SSc remains unclear, envi-
ronmental factors, including infectious agents, seem to have
a crucial role in the onset and/or progression of disease. The
“infection hypothesis” has been studied extensively and a
possible role of some viruses, such as cytomegalovirus
(Arcangeletti et al., 2018; Lunardi et al., 2006), Epstein-Barr
virus (EBV) (Farina et al., 2014, 2017), and parvovirus B19
(B19V) (Ferri et al., 1999; Ohtsuka and Yamazaki, 2004) has
been suggested in the pathogenesis of SSc.
B19V is a small nonenveloped single-stranded DNA virus
with an icosahedral capsid composed of two structural pro-
teins, VP1 and VP2, differing from each other for a sequence
of 227 amino acids at the amino-terminal of the VP1 protein,
called the VP1-unique region (Agbandje et al., 1994). The
major nonstructural viral protein, NS1, is involved in viral
replication and in the pathogenesis of some B19V-associated
diseases (Kerr, 2016).
B19V infection is associated with a wide range of clinical
manifestations, including erythema infectiosum, arthralgia
and arthritis, transient aplastic crisis, and chronic bone
marrow failure (Young and Brown, 2004). After primary
infection, B19V DNA persists lifelong in several tissues,
mainly and in particular in bone marrow, heart, liver,estigative Dermatology. www.jidonline.org 2125
Table 1. Characteristics of Patients and Controls
Characteristic
Patients with
SSc
Healthy
Subjects
Number (n) 19 8
Age, years (median [range]) 55 [38e60] 49 [38e61]
Sex, n (%) — —
Male 3 (16) 2 (25)
Female 16 (84) 6 (75)
B19 antibody status, n (%) — —
IgGþIgM- 13 (76) 4 (50)
IgGeIgM- 4 4
IgGeIgMþ 0 0
Unviable 2 —
Viral DNA, n (%) 2 (11) 2 (25)
Disease duration, years (median [range]) 6[1e19] —
Clinical subgroups, n (%) — —
Diffuse cutaneous 5 (26) —
Limited cutaneous 14 (74) —
Clinical manifestations, n (%)
Raynaud phenomenon 19 (100) —
Digital ulcers 9 (47) —
Puffy fingers 10 (53) —
Telangiectasia 12 (63) —
Interstitial lung disease 10 (53) —
Esophageal dysfunction 13 (68) —
Arthralgia 11 (58) —
Sicca syndrome 14 (74) —
Modified Rodnan skin score (median
[range])
8 [0e33] —
Autoantibodies, n (%) — —
Positive ANA 18 (95) —
Positive ACA 7 (37) —
Positive anti-SCl70 7 (37) —
Treatment, n (%) — —
Steroids (low dosage) 3 (16) —
Prostanoids 16 (84) —
Bosentan 5 (26) —
Calcium antagonist 13 (68) —
Abbreviations: ACA, anti-centromere autoantibodies; ANA, anti-nuclear
autoantibodies.
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2126synovia, and skin (Norja et al., 2006). The functional con-
sequences of such persistence are still unknown. A patho-
genic role of chronic B19V infection in some autoimmune
diseases has been suggested by the presence of typical clin-
ical features and/or autoantibodies in patients with an
ongoing B19V infection. Consequently, it was supposed that
the persistence of the virus might be responsible for the in-
duction of autoimmunity, mainly through a molecular mim-
icry mechanism (Lunardi et al., 1998).
The hypothesis that B19V can contribute to the onset and/
or evolution of SSc is further supported by a number of
studies reporting that B19V DNA persists more frequently in
the bone marrow and skin of patients with SSc compared
with control subjects (Ferri et al., 1999; Ohtsuka and
Yamazaki, 2004) and that anti-B19V NS1 antibodies,
markers of persistent infection, are more frequently detected
in patients with SSc compared with controls (Ferri et al.,
1999). Moreover, the presence of mRNA for B19V and for
tumor necrosis factor-a (TNF-a) was demonstrated in endo-
thelia, fibroblasts, and perivascular inflammatory cells
(Magro et al., 2004), and a limited B19V replication was
reported in the monocytic U937 cell line. (Munakata et al.,
2006). In vitro studies have demonstrated that B19V is able
to infect normal human fibroblasts and endothelial cells
(Zakrzewska et al., 2005), and B19V DNA can persist in SSc
fibroblasts (Ferri et al., 2002a). Although these data suggest
the possible involvement of B19V in SSc, the mechanism by
which the virus interferes in the disease’s pathogenesis re-
mains unclear.
In this study, we investigated whether B19V is able to
induce the activation of caspase-1edependent inflammatory
pathways in human monocytes and whether these pathways
are differently activated in patients with SSc compared with
healthy controls.
RESULTS
Patients and controls
The main characteristics of patients with SSc and controls are
reported in Table 1.
B19V infection of primary monocyte cultures and monocytic
THP-1 cells
As a first step, we investigated whether primary cultured
CD14þ monocytes are susceptible to B19V infection.
CD14þ cells, isolated from the buffy coats of normal do-
nors, were infected with B19V and analyzed at different
time points post-infection for the presence of viral DNA and
mRNAs. Parallel infections were performed using the THP-1
cell line.
Neither CD14þ nor THP-1 cells were able to sustain the
replication of the viral genome or its transcription, as the
levels of B19V DNA at the end of the absorption/penetration
period (T0) did not increase at any time (see Supplementary
Figure S1 online), and no viral mRNAs were observed.
B19V activates NLRP3 inflammasome in THP-1 cells
To provide evidence that B19V activates inflammasome
pathways, we used THP-1 cells differentiated with phorbol
12-myristate 13-acetate as a consolidated model for inflam-
masome studies (Chanput et al., 2014). The cells were
infected with B19V, and the mRNA expression ofJournal of Investigative Dermatology (2019), Volume 139inflammasomes frequently involved in viral infections, such
as NLRP3, AIM2, and IFI16 (Chen et al., 2018; Torii et al.,
2017), was evaluated by reverse transcriptaseePCR. After 6
hours post-infection, the NLRP3 mRNA was significantly
increased compared with mock-infected cells, whereas AIM2
and IFI16 mRNA were not upregulated (Figure 1a).
To investigate whether B19V is able to activate caspase-1
in the context of the NLRP3 inflammasome, we infected
the cells in the absence or presence of glybenclamide, a
specific NLRP3 inhibitor (Chen et al., 2018). Western blot
analysis revealed that B19V induces the cleavage of a
caspase-1 precursor that was completely inhibited by gly-
benclamide (Figure 1b). Comparable data were obtained by
measuring caspase-1 activity using the Caspase-Glo 1
Inflammasome Assay (Promega, Madison, WI) (Figure 1c).
Moreover, B19V infection of THP-1 cells induces caspase-
1edependent cleavage of the proeIL-1b precursor in mature
IL-1b; this phenomenon was inhibited by glybenclamide and
by the specific caspase-1 inhibitor YVAD-CHO (Figure 1d).
Figure 1. Inflammasome-related
proteins and gene expression in
B19V-infected THP-1 cells. (a) The
bar graph shows fold changes of
mRNA expression (NLRP3, AIM2, and
IFI16 genes) compared with that of
uninfected cells of three different
experiments (mean  SE). (b) B19V-
infected (B19V) or control-uninfected
(mock) cells were cultured in the
absence or presence of 100 mM Glyb,
200 mM YVAD-CHO, or DMSO for 6
hours. Western blot analysis using
antibodies to caspase-1 or b-tubulin as
loading control: bar graph shows the
densitometric analysis of six
experiments. (c) Caspase-1 activity
determined by Caspase-Glo 1
Inflammasome Assay: bar graph
shows the results of three experiments
(mean  SE). (d) Western blot analysis
using antibody to IL-1b or to
b-tubulin: bar graph shows the
densitometric analysis of three
experiments. Statistical analysis was
performed by ANOVA and paired t
test. ANOVA, analysis of variance;
B19V, parvovirus B19; Glyb,
glybenclamide; SE, standard error.
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from patients with SSc
Next, we investigated whether B19V activates caspase-1 in
CD14þ cells from patients with SSc or healthy controls. At 6
hours post-infection, a quantitative determination of viral
DNA and mRNAs was carried out by PCR and reverse
transcriptaseePCR, respectively, and levels of caspase-1 ac-
tivity were measured through a functional Caspase-Glo 1
Inflammasome Assay.
The amount of viral DNA detected in infected monocytes
ranged from 1.98E þ 05 to 5.25E þ 08 (median, 1.42E þ 07).
There was no difference in the viral load between patients
and controls (median, 1.86E þ 07 and 1.07E þ 07, respec-
tively). Moreover, no B19V mRNAs were detected in the
infected cells. The NLRP3 mRNA showed a significant in-
crease at 6 hours post-infection compared with mock-
infected cells; in contrast, no upregulated expression of
AIM2 and IFI16 was observed (Figure 2a).
B19V infection of CD14þ cells from patients with SSc
induced an increase in caspase-1 activation, which was
completely inhibited in the presence of YVAD, a specific
caspase-1 inhibitor (Figure 2b). No significant differences
were detected in monocytes from healthy controls compared
with monocytes from control cultures.
Cytokine production is induced by B19V infection in
monocytes from patients with SSc and controls
Because B19V infection induces caspase-1 activation, we
investigated whether the virus can also induce the production
of mature IL-1b in CD14þ monocytes from patients with SSc
or from healthy donors. For this purpose, we collected the
supernatants of mock-infected or B19V-infected cultures andmeasured the concentrations of mature IL-1b by Immunoplex
array. The concentrations of other pro-inflammatory cyto-
kines, such as TNF-a, IL-6, and IL-8, whose production is
often activated by mature IL-1b (Stylianou and Saklatvala,
1998), were also measured.
No increase in IL-1b production was observed in B19V-
infected CD14þ monocytes either from patients with SSc or
from healthy donors (Figure 3a). The production of TNF-a
was significantly induced by B19V infection in monocytes
from patients with SSc. In contrast, only two of eight of
cultures from healthy controls showed increased production
of TNF-a, and statistical analysis did not reveal significant
differences compared with mock-infected cells (Figure 3b).
The B19V-induced production of TNF-a positively correlated
with the amount of viral DNA detected at the end of incu-
bation time (Figure 3c and d), suggesting a role for viral DNA
in cytokine production, likely through the activation of toll-
like receptor (TLR) 9. In fact, using the HEK-293XL cell line
expressing human TLR9 and viral DNAebearing vector, we
were able to demonstrate the activation of the TLR9 signal
(see Supplementary Figure S2 online).
The production of IL-6 and IL-8 was induced by virus
infection in monocytes from patients with SSc, but statistical
analysis did not reveal significant differences compared with
control cultures (data not shown).
B19V infection potentiates lipopolysaccharide-induced
inflammatory response
Emerging evidence has suggested that, in vivo, monocytes of
patients with SSc may be activated by factors released from
damaged endothelial cells (O’Reilly, 2018). These danger-www.jidonline.org 2127
Figure 2. Inflammasome-related
gene expression and caspase-1
activity of B19V-infected CD14D
cells from patients with SSc or
healthy controls. (a) The bar graph
shows fold changes of mRNA
expression (NLRP3, AIM2, and IFI16
genes) compared with that of control
cells of three different experiments
(mean  SE). mRNA expression was
quantified by RT-PCR at 6 hours p.i.
(b). Caspase-1 activity was determined
by Caspase-Glo 1 Inflammasome
Assay. Results are expressed as RLUs.
The boxes extend from range IQR*1.5,
with a horizontal line at the median
and an asterisk indicating the mean
value. Statistical analysis was
performed by Wilcoxon rank test for
paired samples and Friedman test
(Bonferroni correction); P < 0.05 was
considered significant. B19V,
parvovirus B19; IQR, interquartile
range; p.i., post-infection; RLU,
relative luminescence unit; RT-PCR,
reverse transcriptaseePCR; SE,
standard error; SSc, systemic sclerosis.
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2128associated molecular patterns can trigger TLR4 and initiate
pro-inflammatory signals (Chen and Nuñez, 2010). To
reproduce in vitro the stimulation conditions that are likely
active in vivo, we used suboptimal doses of lipopolysac-
charide (LPS), the main TLR4 ligand, to activate monocytes at
the same time as infection with B19V.
In the presence of LPS, B19V infection induced a signifi-
cant increase in IL-1b production in CD14þ monocytes from
17 of 19 patients with SSc compared with cultures stimulated
with LPS alone. LPS-stimulated monocytes from four of eight
normal donors also increased their IL-1b production
following infection, but the analysis of the whole data did not
reveal significant differences (Figure 4a). In addition, LPS-
stimulated monocytes also increased TNF-a production
following infection with B19V, and this increase reached
statistical significance in monocytes from patients with SSc
but not in monocytes from controls (Figure 4b).
Cytokine production by monocytes from patients with SSc
and correlation with clinical parameters
Because the cytokine profile of peripheral blood mono-
nuclear cells (PBMCs) from patients with SSc may be asso-
ciated with selected clinical manifestations (Dantas et al.,
2018), we evaluated whether caspase-1 activation and
cytokine production by monocytes from patients with SSc
correlated with the main clinical manifestations of the dis-
ease. We found a positive correlation between the levels of
caspase-1 activity induced by B19V infection in LPS-
stimulated monocytes and the disease’s duration, particu-
larly in anti-B19V IgG-positive patients (Figure 5aec).
Moreover, the caspase-1 activation following virus infection
in LPS-stimulated monocytes was much higher in patients
with a disease duration of more than 3 years compared with
recently diagnosed patients (Figure 5d). Finally, the caspase-1
activation following virus infection in LPS-stimulatedJournal of Investigative Dermatology (2019), Volume 139monocytes was much higher in patients with sicca syndrome
(Figure 5e).DISCUSSION
Different studies have demonstrated the role of the inflam-
masome in the development of fibrosis (Gasse et al., 2007;
Pan et al., 2019; Zhang et al., 2019). The upregulation of at
least 40 genes involved in the inflammasome pathway and
NLRP3-mediated secretion of IL-1b and IL-18 were detected
in scleroderma fibroblasts (Artlett et al., 2011).
Many viruses can activate inflammasomes (Delaloye et al.,
2009; Ichinohe et al., 2010; Muruve et al., 2008), and it has
been hypothesized that persistent infection and chronic
inflammasome activation is involved in the pathogenesis of
SSc (Artlett et al., 2011).
B19V can infect the SSc target cells (fibroblasts and
endothelial cells) (Zakrzewska et al., 2005) and frequently
persists in the bone marrow and skin of patients with SSc
(Ferri et al., 1999; Ohtsuka and Yamazaki, 2004).
In this study, we demonstrated that B19V is able to induce
NLRP3 gene expression, NLRP3-dependent caspase-1 acti-
vation, and caspase-1emediated IL-1b secretion in THP-1
cells differentiated with phorbol 12-myristate 13-acetate.
Monocytes from patients with SSc highly express the NLRP3
gene and activate caspase-1 following B19V infection.
Compared with THP-1 cells, however, they need additional
stimuli to increase their IL-1b production, suggesting that
B19V infection is not sufficient per se to activate the
expression of the IL-1b gene. A significant increase in IL-1b
production in B19V-infected monocytes from patients with
SSc occurred only after LPS stimulation of infected cells.
Based on these data, we suggest that additional stimuli (in
our experimental model, LPS) are required to induce the
expression of some cytokine genes. Supporting this
Figure 3. IL-1b and TNF-a production in monocytes from patients with SSc or healthy controls. (a) IL-1b and (b) TNF-a production were determined by
Immunoplex array in supernatants of B19V-infected (B19V) or uninfected control (Mock) cultures from patients and healthy controls at 6 hours p.i. Results are
expressed as RLUs. The boxes extend from range IQR*1.5, with a horizontal line at the median and an asterisk indicating the mean value. Statistical
analysis performed by Wilcoxon rank test for paired samples. (c) B19V DNA amount and TNF-a production at 6 hours p.i. in patient’s (ID 0-19) and control’s (ID
c2-c9) monocytes. (d) Relationship between TNF-a (stimulation index) and B19V DNA amount in patients and controls; P < 0.05 was considered significant.
B19V, parvovirus B19; IQR, interquartile range; p.i., post-infection; RLU, relative luminescence unit; SSc, systemic sclerosis; TNF-a, tumor necrosis factor-a.
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also amplified TNF-a production. Recently, De Nardo and
colleagues (2009) reported that signaling crosstalk between
TLR4 and TLR9 amplifies the inflammatory response of
macrophages. In particular, LPS pretreatment primes the in-
flammatory response (e.g., TNF-a production) of mouse
macrophages to the CpG DNA, the main TLR9 ligand.
In vivo, monocytes of patients with SSc may be activated by
factors released from damaged endothelial cells that have
become apoptotic but have not been cleared appropriately
(O’Reilly, 2018). These danger-associated molecular patterns
bind TLR4 and initiate pro-inflammatory signals (Chen and
Nuñez, 2010), eventually potentiated by viral infections.
Thus, we can speculate that B19V activates molecular path-
ways, including the TLR9 pathway, which might synergize
with those activated by LPS or other endogenous or exoge-
nous TLR4 ligands.
The activation of caspase-1 and cytokine production was
rarely observed in B19V-infected monocytes from controls, in
both the absence and presence of LPS, indicating that SSc
monocytes are more sensitive to stimulus than are normal
monocytes.It should be emphasized that markers of infection with
other viruses such as EBV and cytomegalovirus are
frequently detected in patients with SSc (Farina et al., 2014;
Fattal et al., 2014). Recently, it has been reported that 50% of
scleroderma patients have an active EBV infection and that
EBV DNA is present in almost all scleroderma monocytes
(Farina et al., 2017). It has been also demonstrated that EBV
activates the AIM2 inflammasome in human monocytes
(Torii et al., 2017).
The ability of B19V to activate the NLRP3 inflammasome
discloses the autoinflammatory side of SSc, which might
contribute to its multistep, multifactorial pathogenesis on
an autoimmune basis (De Santis and Selmi, 2015; Ferri
et al., 2018). In this regard, it is not surprising that the
caspase-1 activation indexes are more marked in patients
with a long-term disease, in which the combined action of
danger-associated molecular patterns and other triggers
including viral infections places the circulating monocytes
in a state of preactivation, able to amplify the levels and
even the duration of the inflammatory response. Finally, it is
important to note that caspase-1 activation induced by
B19V is more evident in patients with sicca syndrome.www.jidonline.org 2129
Figure 4. B19V potentiates IL-1b and
TNF-a production in cultured
monocytes stimulated with LPS from
patients with SSc. (a) IL-1b and (b)
TNF-a production was determined by
Immunoplex array in supernatants of
LPS-stimulated and B19V-infected
(LPS þ B19V) or LPS-stimulated and
uninfected (LPS) monocytes from
patients or controls at 6 hours p.i. The
boxes extend from range IQR*1.5,
with a horizontal line at the median
and an asterisk indicating the mean
value. Statistical analysis was
performed by Wilcoxon rank test for
paired samples; P < 0.05 was
considered significant. B19V,
parvovirus B19; IQR, interquartile
range; LPS, lipopolysaccharide; p.i.,
post-infection; SSc, systemic sclerosis;
TNF-a, tumor necrosis factor-a.
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pathogenetic factors may be responsible for each SSc
symptom and/or for different disease phenotypes (Ferri
et al., 2018). Further studies on a greater number of pa-
tients are needed, however, to support this hypothesis and
maybe to reveal novel correlations.
One unanswered question is which viral component is
responsible for the monocyte activation observed in our
study? In a recent study, B19V NS1 stimulation of PBMCs
from adult-onset Still disease induced significant upregula-
tion of mRNA levels of NLRP3, caspase-1, and IL-1b, and the
secretion of respective proteins, compared with PBMCs from
healthy controls. (Chen et al., 2018).
Because no B19V gene expression was observed in THP-1
cells and monocytes, we hypothesize that viral structural
components, such as capsid VP1/VP2 proteins and/or viral
DNA, may be involved in this phenomenon.
It has been demonstrated that the B19V VP1-unique region
domain, located on the outside of the capsid (Kawase et al.,
1995), presents phospholipase A2 activity that is necessary
for viral infectivity (Zádori et al., 2001) and is involved in
inflammatory reactions (Canaan et al., 2004; Dorsch et al.,
2002; Lu et al., 2006).
An in silico study (Lanini et al., 2011) reported that B19V’s
CpG index is very high compared with other DNA viruses,
suggesting that B19V can strongly stimulate TLR9-dependent
innate immunity. Moreover, using the HEK-293XL cell line
expressing human TLR9, we were able to demonstrate the
activation of the TLR9 signal induced by B19V DNA (see
Supplementary Figure S2).
Therefore, we can speculate that the monocyte activa-
tion observed in this study might be due to the stimulation
effect of the VP1-unique region protein and/or viral
DNA sequences, a hypothesis needing further in-depth
studies.
As mentioned previously, the pathogenesis of SSc may
recognize a multifactorial (genetic, infectious, and/or envi-
ronmental factors) and multistep process, which may include
the B19V infection. The virus might be involved at different
pathogenetic steps of the disease, including the impairedJournal of Investigative Dermatology (2019), Volume 139bone marrow production of endothelial cell precursors, as
well as the endothelial and fibroblast activity. The B19V-
mediated activation of inflammatory pathways in mono-
cytes, demonstrated in this study, might strongly contribute to
the disease progression and/or development of specific clin-
ical phenotypes.
MATERIALS AND METHODS
Patients and controls
This study included 19 unselected patients with SSc (16 women and
3 men, ranging from 38 to 60 years, median age: 55 years)
consecutively referred to the Rheumatology Unit, University-
Hospital Policlinico of Modena, Italy. All patients fulfilled the
2013 American College of Rheumatology/European League Against
Rheumatism criteria for SSc and were classified according to the
extent of skin involvement as limited SSc or diffuse SSc (van den
Hoogen et al., 2013). Clinical, epidemiological, and serological
investigations, including the modified Rodnan skin score to evaluate
the extent of skin fibrosis (Clements et al., 1995; Khanna et al.,
2017), the main visceral organ involvement, and SSc-associated
autoantibodies, were carried out according to standardized meth-
odologies (Ferri et al., 2002, 2014); clinical and serological features
referred to at the time of this study were thoroughly reviewed from
patients’ medical records.
Eight age- and sex-matched healthy subjects were enrolled as
controls. The study was conducted in accordance with the Decla-
ration of Helsinki and was approved by the local Institutional Re-
view Board and Area Vasta Emilia Nord Ethical Committee (project
identification code: 2742016). Participants gave their written
informed consent.
Laboratory investigations
Peripheral blood samples (12 ml) were collected from each patient
and control. The DNAwas extracted from 100 ml of sample using the
High Pure PCR Template Preparation Kit (Roche Diagnostics, Milan,
Italy), and detection of B19V DNA was performed by real-time PCR
using the Parvovirus B19 ELITe MGB Kit (EliTechGroup, Puteaux,
France). The detection of serum anti-B19V antibodies was carried
out using the Novagnost Parvovirus B19 IgG/IgM ELISA kit BEP III
System (Siemens Healthcare GmbH, Erlangen, Germany).
Figure 5. Caspase-1 activity induced
by B19V infection in LPS-stimulated
monocytes from patients with SSc. (a)
Caspase-1 activity in monocytes from
all patients. (b) Relationship between
caspase-1 activity and duration of
disease. (c) Relationship between
caspase-1 activity and disease
duration in patients who are anti-
B19V/IgG-positive. (d) Caspase-1
activity in monocytes from patients
with SSc with disease duration <3
years or >3 years and (e) with or
without sicca syndrome. Data are
expressed as RLU and represent the
increase in caspase-1 activity induced
by B19V infection in LPS-treated
cultures compared with cultures
treated with LPS alone (stimulation
indexes). The boxes extend from range
IQR*1.5, with a horizontal line at the
median and an asterisk indicating the
mean value. Statistical analysis was
performed by Mann-Whitney U test
(exact test); P < 0.05 was considered
significant. B19V, parvovirus B19;
IQR, interquartile range;
LPS, lipopolysaccharide;
LU, luminescence units;
SSc, systemic sclerosis
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PBMCs were obtained by Ficoll-Hypaque density gradients of blood
samples from patients and controls and from buffy coats provided by
AOU Careggi as previously described (Clemente et al., 2011).
CD14þ cells were isolated from PBMCs using anti-CD14þ conju-
gated microbeads (Miltenyi Biotec, Bergisch Gladbach, Germany)
(Clemente et al., 2013). Cells were cultured in RPMI-1640 medium
supplemented with 10% fetal bovine serum and antibiotic mix
(penicillin, 10,000 U/ml; streptomycin, 10 mg/ml), here referred to
as complete medium (CM) at 37 C with CO2.
THP-1 cells were obtained from ATCC (Manassas, VA) and
cultured in CM. Cells were treated with phorbol 12-myristate 13-
acetate (300 ng/ml) for 30 minutes before their use.
B19V infection
For in vitro infection, viremic plasma samples from healthy donors
containing a high titer of B19V (1E þ 11e1E þ 12 genome equiv-
alents/ml), kindly donated by Professor Modrow (Germany) and by
Kedrion S.p.A. (Italy), were used as a source of B19V.
CD14þ or THP-1 cells were cultured in CM at a density of 2  106
cells/well and incubated for 2 hours with B19V viremic plasma at a
multiplicity of infection of 1,000 genome equivalents/cell, with or
without LPS (500 ng/ml). As controls, cells treated with only LPS or
with B19V-negative plasma were used. Following the adsorption/
penetration period (T0), the cells were washed with phosphate
buffered saline and incubated in CM. At T0 and at different time
points, the cells were lysed for protein, DNA, or RNA extraction.
Nucleic acid extraction and amplification
The B19V DNA extracted from cell cultures using E.Z.N.A. Tissue
DNA Kit (Omega Bio-tek, Norcross, GA) was quantified by real-time
quantitative PCR (Toppinen et al., 2015). For quantification,dilutions of pHRT-1 plasmid, kindly donated by Professor Gallinella
(University of Bologna), were used. To check DNA extraction and
amplification, all samples were analyzed by real-time PCR for the
Adaptor Related Protein Complex-3 Subunit Beta-1 sequence (Bio-
Rad, Hercules, CA) (Arvia et al., 2017).
The RNA extracted from cultured cells using the E.Z.N.A. Total
RNA Kit 1 (Omega Bio-tek, Norcross, GA) was retro-transcribed
using the PrimeScript RT reagent kit with gDNA Eraser (Takara
Clontech, St-Germain-en-Laye, France) and analyzed for the pres-
ence of spliced transcripts of B19V VP1 protein by real-time PCR
modified from Nguyen et al. (2002). To detect and quantify B19V
NS1 mRNA, cDNA was amplified by real-time PCR as described
previously. To quantify mRNA for 18S, NLRP3, AIM2, and IFI16,
reverse transcriptaseePCRs were carried out using PrimePCR SYBR
Green Assay (Bio-Rad, Hercules, CA).
Cytokine production and caspase-1 activity studies
CD14þ cells (2  105 cells) from patients with SSc or controls were
infected with B19V in the absence or presence of LPS (500 ng/ml).
Cells were washed with phosphate buffered saline and incubated
with CM for an additional 4 hours. Supernatants were collected, and
cytokine concentration was determined using a Milliplex kit (Merck
KGaA, Darmstadt, Germany) and Bio-Plex (Bio-Rad, Hercules, CA)
apparatus. Caspase-1 activity was measured in cell cultures in the
presence or absence of 60 mM YVAD using the Caspase-Glo 1
Inflammasome Assay.
Western blot
B19V-infected or control THP-1 cells differentiated with phorbol 12-
myristate 13-acetate (2  106 cells) were cultured with or without
LPS (500 ng/ml), 100 mM glybenclamide, 200 mM YVAD-CHO, or
DMSO (Sigma-Aldrich, St. Louis, MO) for 6 hours, lysed withwww.jidonline.org 2131
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2132radioimmunoprecipitation assay buffer (Thermo Fisher Scientific,
Waltham, MA) in the presence of phosphatase and protease inhibitor
cocktails (Sigma-Aldrich, Saint Louis, MO) and centrifuged at
12,000g. Proteins (40 mg) were loaded onto precast polyacrylamide
TGX Stain-Free gel (Bio-Rad, Hercules, CA), blotted onto poly-
vinylidene difluoride membrane (Bio-Rad, Hercules, CA), and
stained with rabbit anti-caspase-1 (Cell Signaling Technology, Dan-
vers, MA), rabbit antieIL-1b, or antieb-tubulin (Santa Cruz
Biotechnology, Dallas, TX); anti-rabbit IgG (Bio-Rad, Hercules, CA)
was used as a secondary antibody at a 1:3,000 final dilution. The
densitometric analysis was performed using Image Lab software
(Bio-Rad, Hercules, CA).
Statistical analysis
Statistical analyses were performed using Fisher exact test for the
analysis of frequency. Numerical data were expressed as mean 
standard error if they were in normal distribution, or median and
interquartile range if they were not in Gaussian distribution. Mann-
Whitney U test (exact test) and Wilcoxon rank sum test for two-
group comparison or Wilcoxon signed rank test for paired samples
were used to compare differences in cytokine production. Statistical
significance was defined as a P  0.05. Spearman rank correlation
coefficient was used to examine the relationship between two
continuous variables. Analysis of variance and paired t-test were
used to analyze densitometric values of western blot. A probability
value of P  0.05 was considered significant. Statistical analysis was
performed using R software version 3.5.1.
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Supplementary Figure S1. Time course of B19V infection of THP-1 cultures
and cultured CD14D from normal donors. The cells were infected at a
multiplicity of infection of 1,000 geq/cell. Quantitative evaluation of viral
DNAwas done at 2 hours (T0), 6 hours, 24 hours, 48 hours, and 72 hours, and
at 6 days and 8 days p.i. Bars represent mean  SE values from three different
experiments. B19V, parvovirus B19; geq, genome equivalents; p.i., post-
infection; SE, standard error
Supplementary Figure S2. B19V DNA activates TLR9. The HEK-293XL cell
line expressing human TLR9 was stably transfected with a plasmid encoding a
luciferase reporter gene regulated by NF-kB regulatory promoter (pNifty,
Invitrogen, Carlsbad, CA). Cells were plated in triplicate (70,000 cells/well) in
the absence or presence of 0.5 mM ODN 2006 (Invitrogen). Viral
DNAebearing pGEM vector or empty vector was diluted in 0.5 ml of
lipofectamine 2000 and added to the culture at the final concentrations of 1,
0.5, and 0.25 mg/ml. Cells were cultured for 5 hours at 37 C. TLR9-mediated
NF-kB activation was measured as luciferase activity using the Steady-Glow
Luciferase Assay System (Promega, Madison, WI) as directed by the
manufacturer. Absorbance and luminescence were evaluated using a Victor
(PerkinElmer, Waltham, MA) microplate spectrophotometer. Results are
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2133.e1expressed as the fold change (%) in luciferase units relative to control not
stimulated cultures. B19V, parvovirus B19; TLR, toll like receptor.
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